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In Alzheimer disease, neuronal degeneration and the presence of neurofibrillary tangles correlate with the se-
verity of cognitive decline. Neurofibrillary tangles contain the antigenic profile of many cell cycle markers, re-
flecting a re-entry into the cell cycle by affected neurons. However, while such a cell cycle re-entry phenotype is 
an early and consistent feature of Alzheimer disease, the mechanisms responsible for neuronal cell cycle are un-
clear. In this regard, given that a dysregulated cell cycle is a characteristic of cancer, we speculated that altera-
tions in oncogenic proteins may play a role in neurodegeneration. To this end, in this study, we examined brain 
tissue from cases of Alzheimer disease for the presence of BRCA1, a known regulator of cell cycle, and found 
intense and specific localization of BRCA1 to neurofibrillary tangles, a hallmark lesion of the disease. Analysis of 
clinically normal aged brain tissue revealed systematically less BRCA1, and surprisingly in many cases with ap-
parent phosphorylated tau-positive neurofibrillary tangles, BRCA1 was absent, yet BRCA1 was present in all 
cases of Alzheimer disease. These findings not only further define the cell cycle reentry phenotype in Alzheimer 
disease but also indicate that the neurofibrillary tangles which define Alzheimer disease may have a different 
genesis from the neurofibrillary tangles of normal aging.   
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1.  Introduction 
  Neurofibrillary tangles (NFT) are the cardinal 
intracellular lesion of Alzheimer disease (AD), and are 
also found in normal aging, albeit to a lesser extent. 
Highly phosphorylated tau protein is considered the 
predominant proteinaceous component of NFT [1], 
however, numerous other proteins have also been lo-
calized to these lesions including neurofilaments [2], 
ubiquitin [3, 4], amyloid-β [5], and cell cycle markers 
[6-11]. Notably, NFT associated with normal aging are 
viewed as being quantitatively different, but qualita-
tively identical [12]. Whether the mechanisms respon-
sible for the genesis of NFT in AD are similar or dif-
ferent from the genesis of NFT in normal aging is un-
known.  
  BRCA1 is expressed in dividing neuronal cells 
during development, and is present in smaller 
amounts in fully differentiated cells [13]. BRCA1 is 
known to regulate transcription, regulate cell cycle 
progression, and may even have a role in maintaining 
telomere function and as such the presence of BRCA1 
is indicative of cell cycle changes and DNA damage, 
both of which are pathogenic changes in AD. Nucleic 
acid damage is well-documented in AD, specifically 
within the pyramidal neurons, the population suscep-
tible to neurodegeneration and death [14-18]. Conse-
quently, tumor suppressor proteins such as p21, p27, 
p53 are activated by BRCA1, are indicative of DNA 
damage [19], and are activated in AD [6, 20]. Such tu-
mor suppressors play a role in suppression of the cell 
cycle and cell survival instead of apoptosis and their 
presence may be a neuroprotective factor to prolong 
the life of the cell after re-entry into the cell cycle, pro-
tecting neurons from completion of apoptosis [21]. 
These proteins have come to the forefront as molecu-
lar candidates to be used in discrimination between 
normal aging and pathological diseases. Neuroprotec-
tive factors have also been suggested as a possible 
target for drug design efforts with the goal of halting 
the progression of the cell cycle and delaying apop-
tosis. [22-24]. BRCA1 is also associated with a spec-
trum of functions related to the preservation of ge-
nomic stability [25]. For example, BRCA1 is involved 
in transcriptional activation and growth inhibition 
[26-28], transcription coupled repair (TCR) of oxida-
tive damage to DNA and other DNA repair [29, 30], 
and association with γ-tubulin, a central component of 
the microtubule organizing center and centrosomes, 
thus implying a regulatory role in G2/M progression 
[31]. There are also a host of putative functions as-
signed to BRCA1 based on its structure and associa-
tions. Among these include association with BARD1, 
cyclin A and cyclin D kinases which phosphorylate 
BRCA1 [32]. Int. J. Med. Sci. 2007, 4 
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  Many of these known functions of BRCA have 
also been associated with AD. Oxidative DNA dam-
age, as well as RNA damage [15, 16], has been well 
documented in the aging brain, contributing to the 
development of AD [18]. Further, even cases of mild 
cognitive impairment display the same abnormalities, 
prompting the search for increased DNA repair 
mechanism in cases of neurodegeneration [33]. Evi-
dence of cell cycle dysfunction and the oxidative DNA 
damage profile in AD caused speculation that BRCA1 
may play a role in disease pathogenesis. 
  There are clearly a number of striking parallels 
between AD and cancer, including age, and likely 
multiple etiologies and risk factors [34]. As for cancer, 
the notion of a “two-hit” hypothesis has also been 
proposed [35, 36]. The latter may separate AD from 
normal aging. Indeed, while cells, in this case neurons, 
have the capacity to maintain homeostatic balance and 
function under condition of stress, several “hits” may 
disrupt the cells’ regeneration capacity leading to 
neurodegeneration and death. This stress may be oxi-
dative insult or metabolic inefficiency. Possibilities for 
other “hits” include genetic mutations in apolipopro-
tein E, presenilins, or amyloid-β protein precursor, 
hormonal dysregulation, environmental or education 
status, inflammatory responses, or perhaps even the 
induction of oncogenic-like pathways [37]. To this end, 
we found that the BRCA1 protein is strongly associ-
ated with NFT in AD yet a feature of only about half 
of the cases of normal aging containing tau-positive 
NFT. Elevations in BRCA1 in neurons in AD may 
represent an attempt towards homeostasis by the cell, 
working with other factors to halt the cell cycle and 
mediate DNA repair. Interestingly, a much higher 
proportion of NFT were labeled in AD cases than in 
control cases. These findings hint at differential 
mechanisms of NFT genesis in AD and in normal ag-
ing and/or distinct cellular responses to these 
changes. 
2.  Materials and Methods 
  Hippocampal and cortical specimens were ob-
tained postmortem from patients with histopa-
thologically confirmed AD (n = 33, age 65-93, mean 
82.3) and control (n = 28, age = 47-89, mean 73.5). Tis-
sue was fixed either in 10% buffered formalin or in 
methacarn (methanol:chloroform:acetic acid, 6:3:1), 
and embedded in paraffin. 6μm sections were depar-
affinized in xylene and rehydrated in graded alcohol, 
the endogenous peroxidase activity eliminated by in-
cubation in 3% hydrogen peroxide in methanol for 30 
min, and finally to Tris buffered saline (TBS, 50 mM 
Tris, 150 mM NaCl, pH=7.6). Sections were blocked in 
10% normal goat serum (NGS) for 30 min followed by 
overnight incubation with primary antibody in 1% 
NGS at 4°C in a humidified chamber. Staining was 
completed using the peroxidase-anti-peroxidase pro-
cedure with 3,3-diaminobenzidine (DAB) as chroma-
gen, and sections were dehydrated and mounted with 
permount. 
  Antibodies used included monoclonals recog-
nizing BRCA1 amino acids 1-304 (Clone MS110, On-
cogene Research Products), rabbit polyclonal against 
phosphorylated BRCA1 amino acids 1489-1500 (Up-
state Cell Signaling Solutions), and phosphorylated 
tau (AT8, Endogen) to label NFT.   
  Antibody specificity for BRCA11-304 was con-
firmed by performing an adsorption experiment with 
its corresponding antigen. Diluted antibody was in-
cubated overnight with 20μg of BRCA1 peptide and 
applied to an adjacent section with antibody alone. 
Additionally, cross-adsorption with purified tau pro-
tein was performed as well as omission of primary 
antibody. 
  To further analyze the presence of BRCA1 in 
cases of control, mild cognitive impairment, as well as 
AD, formalin fixed blinded sections were analyzed for 
BRCA1 and phosphorylated tau. Using images ob-
tained with a Zeiss Axiocam and associated image 
analysis software, the number of NFT immunostained 
in 3 fields (1mm
2) encompassing the CA1 and CA2 
areas of the hippocampus were determined.   
3.  Results 
  BRCA1 is found to be specifically and intensely 
localized with intracellular NFT in hippocampal neu-
rons in AD (Figure 1A). In young control cases and 
those without any tau pathology, no cellular staining 
was seen (Figure 1B). The specificity of our findings 
was demonstrated in adjacent sections where BRCA1 
immunoreactivity in NFT (Figure 1C) was completely 
abolished following adsorption with the specific 
BRCA1 peptide (Figure 1D). On the other hand, 
cross-adsorption with tau protein did not diminish the 
immunoreaction (data not shown). BRCA1 localiza-
tion to NFT was detected in all cases of AD, inde-
pendent of fixation methods. 
Hippocampal sections from 17 clinically normal 
cases containing pathological accumulations consis-
tent with normal aging were specifically chosen and 
immunostained for BRCA1 and AT8. It was noted that 
in many of the control cases containing phosphory-
lated tau-positive NFT, BRCA1 was absent. Analysis 
of this series of cases shows that while all cases with 
AD exhibited BRCA1-positive NFT, BRCA1 was pre-
sent to a lesser extent and in smaller and more vari-
able numbers in control cases with pathology across 
all age ranges (Figure 2).   
  To further assess the relationship between 
BRCA1 and AD, blinded sections were stained for 
BRCA1 and AT8 in well characterized cases classified 
as control (no neurological diagnosis), mild cognitive 
impairment (MCI) and AD. The numbers of NFT 
stained for each marker in three fields were quantified 
using a computer assisted image analysis (Figure 3) 
and expressed as the percentage of BRCA1 positive 
compared to AT8 positive NFT. In control cases (n = 4, 
age range 83-93), an average of only 9% of NFT con-
tained BRCA1. In cases with MCI (n = 3, age range 
78-96), 18% of NFT were BRCA1 were positive, and in 
cases of AD (n = 3, age range 69-91), the number in-
creased to 28%. The percentage of NFT stained in MCI Int. J. Med. Sci. 2007, 4 
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cases is essentially midway between AD and control 
cases consistent with clinical findings that MCI is a 
transition. Nonetheless, as expected, by looking only 
at tau, there was a wide variety of pathology in each 
category. In the control cases, the number of 
tau-positive NFT ranged from 5 to 260, and in AD 
cases, from 39 to 321 NFT. 
 
 
Figure 1. Monoclonal antibody to BRCA1 recognizes intracellular NFT in all cases of AD (A), yet in many control cases, no 
structures are stained (B). On adjacent serial sections, the specific localization of BRCA1 to NFT (C) is completely abolished fol-
lowing adsorption with antigen (D). * marks landmark vessel. Scale bar= 50 μm. 
 
 
 
Figure 2. All AD cases and all clinically normal cases showing 
AT8-positive NFT consistent with normal aging were also 
analyzed for the presence of BRCA1-positive NFT. All AD 
cases (100%) at all age ranges exhibited BRCA1 positive NFT. 
Yet only about half of the control cases with NFT displayed 
BRCA1 positivity. 
    
  The colocalization of AT8 and BRCA1 represen-
tative of the different disease states is shown in Figure 
4 .  A d j a c e n t  s e r i a l  s e c t i o n s  o f  A D  s h o w e d  t h a t  l a r g e  
numbers of NFT are positive for BRCA1 (Figure 4A) 
with significant overlap with AT8 (Figure 4B). In a 
case of MCI, while fewer AT8-positive NFT are pre-
sent (Figure 4D), again there is significant overlap 
with BRCA1 (Figure 4C). As was seen in about half of 
the clinically normal cases with tau pathology, while 
even moderate numbers of AT8-positive NFT are pre-
sent (Figure 4F), BRCA1 (Figure 4E) is not present.   
  Qualitative analysis for the presence of phos-
phorylated BRCA1 (pBRCA1) was also performed. In 
some cases of AD, pBRCA1 stained neuronal nuclei as 
well as a smaller population of NFT (Figure 5B) com-
pared to non-phosphorylated BRCA1 (Figure 5A). Int. J. Med. Sci. 2007, 4 
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Figure 3. The number of NFT stained for BRCA1 and AT8 were counted in the CA1/CA2 regions of hippocampus in well char-
acterized cases of AD (n = 3), MCI (n = 3), and control (n = 4). In AD, an average 28% of AT8-positive NFT contained BRCA1. That 
number was only 18% for cases of MCI and 9% for the control cases. While all four control cases contained AT8-positive NFT, only 
two cases displayed BRCA1, a finding similar to that observed with the aged controls examined in Figure 2. 
 
Figure 4. The localization patterns of AT8 and BRCA1 in the different disease states varies greatly. AD cases show high numbers of 
AT8-positive NFT (B), with many overlapping with BRCA1 localization (A). In cases of MCI, while there are fewer AT8-positive 
NFT (D), many overlap with BRCA1 (C). Yet in about half of the aged control cases, while there are moderate numbers of 
AT8-positive NFT (F), BRCA1 is absent (E). * denotes landmark vessels on adjacent serial sections. Arrow mark NFT labeled for 
both BRCA1 and AT8. Int. J. Med. Sci. 2007, 4 
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Figure 5. Phosphorylated BRCA1 is localized in some cases of AD to both nuclei as well as some NFT (B). In adjacent serial 
sections stained for BRCA1 (A), many of the cells containing NFT (arrows) also contain pBRCA1 (B). * denotes landmark vessel. 
 
4.  Discussion 
  In this study, we show that, controlled for age, 
there is a progression in the percentage of NFT con-
taining BRCA1 from cases with no dementia to MCI to 
AD. MCI cases, by their definition, are in the early 
stages of AD. The differences in BRCA1 and tau 
co-localization in control versus MCI or AD cases may 
point to different etiologies and/or different cellular 
responses. Indeed, mechanisms involved in the for-
mation of  NFT in AD may be very different to the 
process during normal aging, i.e., that the develop-
ment of AD requires two or more “hits”. Neurons can 
maintain normal function and combat assault from 
oxidative damage throughout aging, unless there is 
another “hit”, whether it be a genetic mutation or 
metabolic dysfunction, from which the cell cannot 
overcome and maintain balance, resulting in neuronal 
death. As AD is a disease that can last ten years or 
more, rather than succumbing to apoptosis immedi-
ately, neurons may attempt to survive by initiating 
cell cycle progression, and attempting to control the 
deregulated cell cycle and concurrent apoptotic sig-
naling. BRCA1 is a tumor suppressor protein, in-
volved in DNA repair, suspension of the cell cycle and 
probable temporary delay of apoptosis when prob-
lems are suspected. Since the prevalence of BRCA1 
increases as the disease progresses, transcription of 
BRCA1 may be activated early in the progression of 
AD. This is consistent with the hypothesis that cell 
cycle changes take place very early in the progression 
of the disease, long before the presence of other pa-
thology. Over time, DNA and cell cycle changes may 
compound, and BRCA1 and other protein expression 
increases, eventually resulting in cell death. These 
findings raise the possibility that BRCA1 accumulates 
in neurons early in the disease and only in those cases 
in the early stages of AD and may or may not be in-
dependent of tau formation and the expression of 
other cell cycle markers.   
  The association of BRCA1 with neurodegenera-
tive pathology in AD implicates genomic instability 
and possibly a neuroprotective element in neurons in 
AD. The emerging evidence of genomic instability as a 
proximal feature in the pathogenesis of neurodegen-
eration in AD may possibly be a feature of cell cycle 
instability in neurons [38]. Taken together with the 
association of BRCA1, this phenotype bears many re-
semblances to a mitotic lesion or, at minimum, the 
presence of oncogenic signaling in AD, providing an-
other driving force, or “hit” specific for lesion devel-
opment in AD [36]. The presence of BRCA1 and other 
tumor suppressor proteins is also indicative of protec-
tive mechanisms against the formation of a cancer or 
unnecessary apoptosis.   
  The presence of phosphorylated BRCA1 has 
been characterized under conditions of DNA damage. 
Phosphorylation and changes in subcellular localiza-
tion follow DNA damage in cell models. For instance, 
phosphorylation of specific residues dictate both lo-
calization and function [39], which could be related to 
the varying nuclear accumulations seen in the brain in 
the present study. pBRCA1 has also been implicated 
to play a role in maintaining genomic integrity in mi-
tochondria and in the nucleus [40]. Recent work has 
related these functions specifically to telomere main-
tenance. In BRCA1 -/- cells, telomere dysfunction evi-
denced by a loss of telomere repeats was found [41], a 
distinctive feature of degenerating neurons in the AD 
brain [42]. 
  While the mechanisms responsible for the local-
ization of BRCA1 to NFT remain to be determined, 
one intriguing hypothesis is that the presence of 
BRCA1 signifies a neurogenic/oncogenic stimulus 
that is found in AD and other neuropathology. In this 
regard, there are several examples showing cognitive 
improvements in dementia patients undergoing che-
motherapy [43]. It would be interesting to investigate 
the therapeutic efficacy of combination or simply 
agent antimitotic therapy with vincristine, carmustine, 
melphalan, cyclophosphamide, or prednisone for AD 
[44].  
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